Drug Profile
Research programme: multidrug-resistant infection therapeutics - Summit Therapeutics
Alternative Names: Antibiotics - Summit Therapeutics; DDS 01; DDS-03; SMT 026571; SMT 571Latest Information Update: 25 Mar 2022
Price :
$50
*
At a glance
- Originator Discuva
- Developer Summit Therapeutics
- Class Antibacterials; Small molecules
- Mechanism of Action Cell division modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
- Discontinued Gonorrhoea
Most Recent Events
- 24 Mar 2022 Summit Therapeutics has patent protection and pending patents for Discuva platform technology in USA and other foreign countries
- 14 Jun 2021 Discontinued - Preclinical for Gonorrhoea in United Kingdom (PO), prior to June 2021
- 28 Aug 2020 No recent reports of development identified for research development in Bacterial-infections in United Kingdom (PO)